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Aberrant cholesterol metabolism has been implicated in Alzheimer´s disease (AD). Recent 
findings have suggested an interaction of Niemann-Pick C1 (NPC1) and ATP-binding cassette 
transporter A1 (ABCA1) proteins in intracellular cholesterol transport and in maintaining cell 
cholesterol balance. Underexpression of NPC1 in concert with underexpression of ABCA1 
would result in increased cholesterol accumulation and increased AD risk. We examined a 
functional polymorphism in the ABCA1 promoter region (−477, rs2422493), and four NPC1 
polymorphisms in exon 6 (rs18050810), intron 20 (rs4800488), intron 22 (rs2236707), and intron 
24 (rs2510344) capturing 85% of genetic variability in Hap Map CEU population, in a group of 
631 Spanish AD patients and 731 controls. Subjects carrying both the ABCA1 (−477) TT 
genotype and the NPC1 (exon 6) GG genotype (OR = 1.89; 95% CI 1.04-3.41), NPC1 (intron 
20) AA genotype (OR = 2.05; 95% CI 1.26-3.33), NPC1 (intron 22) AA genotype (OR = 2.05; 
95% CI 1.18-3.58), or NPC1 (intron 24) GG genotype (OR = 1.89; 95% CI 1.16-3.07) had a 
higher risk of developing AD than subjects without these risk genotypes. Testing for epistatic 
interaction between genes in the pathway of cholesterol metabolism might be useful for 
predicting AD risk.  
 











Aberrant cholesterol metabolism has been implicated in Alzheimer´s disease (AD), with 
increased cellular cholesterol levels inducing high amyloid beta (Aβ) production and the 
development of neurofibrillary tangles [1, 2], which are central to the pathogenesis of AD. 
Niemann-Pick C1 (NPC1) protein and ATP-binding cassette transporter A1 (ABCA1) protein 
affect redistributing late endosomal/lysosomal intracellular cholesterol transport to other cellular 
sites including the plasma membrane and the endoplasmic reticulum [3, 4]. The most striking 
biochemical feature of NPC1- or ABCA1-deficient cells is an excessive storage of unesterified 
cholesterol in late endosomes/lysosomes [1, 2]. In recent genome-wide association studies [5, 6], 
genetic markers of the ABCA1 region showed a weak association to AD [5], but markers of the 
NPC1 region were not found associated to AD [5, 6]. In addition, variability in NPC1 [7] and 
ABCA1 [8-12] genes has been proposed to modify the risk of AD through an independent effect. 
However, the interactive effect between polymorphisms of two genes (epistasis) may exist 
without a significant main effect of either of them, and in such cases, the effect would have been 
missed if polymorphisms of both genes had not been tested jointly [13]. Therefore, and 
considering the postulated common pathway of NPC1 and ABCA1 in intracellular cholesterol 
trafficking, we examined the combined contribution of these genes to the susceptibility for AD in 
a case-control study. Our hypothesis is that there may be functional variants in the NPC1 and 
ABCA1 genes that would predispose people to AD due to underexpression of the NPC1 gene in 
concert with underexpression of the ABCA1 gene. We focused on a functional polymorphism in 
the ABCA1 (−477, rs2422493) gene [14] previously associated with AD risk [11, 15], and we 
also examined one NPC1 polymorphism in exon 6 (rs18050810) previously analyzed in AD [7] 
and three other NPC1 polymorphisms in intron 20 (rs4800488), intron 22 (rs2236707), and 




Subjects. The study included 631 AD patients (65% women; mean age at study 75.9 years; SD 
8.1; range 61-109 years; mean age at onset 72.8 years; SD 7.8; range 60-100 years) who met 
NINCDS/ADRDA criteria for probable AD [16]. All AD cases were defined as sporadic because 
their family history did not mention any first-degree relative with dementia. AD patients were 
recruited from the Departments of Neurology of University Hospital “Marqués de Valdecilla” 
(Santander, Spain), and Hospital “La Paz” (Madrid, Spain). The large majority of patients were 
living in the community and had been referred by their general practitioner; few had been 
admitted from hospital wards or nursing home facilities. Control subjects were 731 unrelated 
individuals (65% women; mean age 78.6 years; SD 9.4; range 60-104 years) randomly selected 
from nursing homes. These subjects had complete neurologic and medical examinations that 
showed that they were free of significant illness and had Mini Mental State Examination scores 
of 28 or more, which were verified by at least one subsequent annual following-up assessment. 
The controls arose from the same base population as the cases. The AD and control samples 
were Caucasians originating from a limited geographical area in northern Spain (Santander) and 
from the central area of Spain (Madrid).  
Genotyping. Blood samples were taken after written informed consent had been obtained from 
the subjects or their representatives. The study was approved by the ethical committees of the 
University Hospital “Marqués de Valdecilla” and the Hospital “La Paz”. Genotyping of NPC1 
(rs18050810, rs4800488, rs2236707, and rs2510344) polymorphism was performed by a Taq-
Man single-nucleotide-polymorphism assay (Applied Biosystems, Warrington, Cheshire, UK) 
and an ABI PRISM 7000 or 7900HT sequence detection systems (Applied Biosystems). We 
used data from the HapMap project (http://www.hapmap.org) to select the 4 htSNPs capturing 
85% of NPC1 genetic variability in Caucasians. SNPs were chosen among those with minor 
allele frequencies ≥5% using Haploview v3.2 software 
(http://www.broad.mit.edu/mpg/haploview) with an r2 threshold of 0.8. The ABCA1 (−477, 
rs2422493) polymorphism was determined as described previously [9]. APOE genotyping was 
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performed by amplification of the 4th exon of the APOE gene by PCR with biotinylated primers, 
followed by reverse hybridization on nitrocellulose strips, using the INNO-LIPA ApoE assay 
(Innogenetics NV, Ghent, Belgium), or by HhaI restriction analysis.  
Statistical analysis. Hardy-Weinberg equilibrium (HWE) was calculated in the control 
population using Pearson’s χ2 statistics. We assessed pairwise linkage disequilibrium (LD) 
between the 4 NPC1 htSNPs by D' and r2 statistics.  Haplotype reconstruction and their 
frequencies in cases and controls were estimated by an expectation-maximization algorithm, 
method implemented in Haploview 3.32. Pearson’s χ2 statistics were performed to compare 
genotype, allele, and haplotype distribution of the patients and control for each SNP. Genotypic 
and allelic distributions were assessed by logistic regression using SPSS software. Odds ratios 
(ORs) and p-values adjusted by age, gender and APOE status were also calculated by logistic 
regression. All statistical analyses were performed with the package SPSS 13.0 for Windows 
(SPSS, Inc, Chicago, Illinois). 
 
Results 
Control groups for ABCA1 (−477) (p = 0.57), NPC1 (exon 6) (p = 0.60), NPC1 (intron 20) (p = 
0.99), NPC1 (intron 22) (p = 0.80), and NPC1 (intron 24) (p = 0.75) polymorphisms were within 
the range of Hardy-Weinberg equilibrium. In our Spanish population the four NPC1 
polymorphisms were in strong linkage disequilibrium: exon 6 and intron 20, D´ = 0.99; exon 6 
and intron 22, D´ = 0.96; exon 6 and intron 24, D´ = 0.95; intron 20 and intron 22, D´ = 0.95; 
intron 20 and intron 24, D´ = 0.96; intron 22 and intron 24, D´ = 0.92. When the risk was 
considered for a single polymorphism, the distribution of the allele and genotype frequencies of 
the ABCA1 (−477), NPC1 (exon 6), NPC1 (intron 20), NPC1 (intron 22), and NPC1 (intron 24) 
polymorphisms did not differ significantly between AD and control groups (Table 1). The 
overall frequencies of the NPC1 haplotypes were not statistically different between cases and 
controls (data not shown). However, the subjects carrying both the ABCA1 (−477) TT genotype 
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and the NPC1 (exon 6) GG genotype (OR = 1.89; 95% CI 1.04-3.41; p = 0.034), NPC1 (intron 
20) AA genotype (OR = 2.05; 95% CI 1.26-3.33; p = 0.004), NPC1 (intron 22) AA genotype 
(OR = 2.05; 95% CI 1.18-3.58; p = 0.01), or NPC1 (intron 24) GG genotype (OR = 1.89; 95% 
CI 1.16-3.07; p = 0.01) had a higher risk of developing AD than subjects without these risk 
genotypes, suggesting a gene-gene interaction (Table 2). Since the four NPC1 polymorphisms in 
our study are in almost complete linkage disequilibrium forming one block, we have tested only 
three independent comparisons examining the interaction between the ABCA1 and NPC1 genes; 
therefore, when applying the conservative Bonferroni adjustment, statistical significance should 
be set up at p < 0.017, which is reached by the interaction between ABCA1 (−477) and NPC1 
(intron 20) (p = 0.004), NPC1 intron 22 (p = 0.01), or NPC1 (intron 24) (p = 0.01).  
 
Discussion 
We have shown, for the first time, that the NPC1 and ABCA1 genes may interact in determining 
the risk for AD, with subjects carrying both the ABCA1 (−477) TT genotype and the NPC1 
(exon 6) GG genotype, NPC1 (intron 20) AA genotype, NPC1 (intron 22) AA genotype, or 
NPC1 (intron 24) GG genotype having a higher risk of developing AD. De novo synthesis in 
glial cells is responsible for practically all cholesterol present in the brain, and once synthesized, 
astrocytes secrete the cholesterol predominantly via the cholesterol transporter ABCA1, which 
reduces cellular cholesterol and inhibits Aβ production [17]. The deficiency of ABCA1 results in 
accumulation of cholesterol in cultured glia and elevated Aβ levels in the brain of transgenic 
mouse models of AD [18, 19]. Genetic variants in ABCA1 have been proposed to modify the 
risk of AD [8-12], and homozygosity for the ABCA1 (−477) T allele in concert with 
homozygosity for the HMGCR 5´-UTR (the major rate-limiting enzyme in the novo synthesis of 
cholesterol,) G allele has been associated with increased AD risk [15]. The ABCA1 (−477) 
polymorphism located in the promoter region has a functional effect: luciferase reporter  assay 
indicates that the ABCA1 (−477) C allele has significantly higher promoter activity than the 
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ABCA1 (−477) T allele promoter [14]. So, we hypothesized that subjects carrying the low 
ABCA1 (−477) producer TT genotype might show a higher AD risk due to their genetic inability 
to induce a more effective ABCA1 protective response.  
The present study indicates that an AD risk effect of ABCA1 (−477) producer TT genotype is 
only apparent in the presence of NPC1 (exon 6) GG genotype, NPC1 (intron 20) AA genotype, 
NPC1 (intron 22) AA genotype, or NPC1 (intron 24) GG genotype. In a preliminary study 
conducted in the Polish population, there were gradients of two non-synonymous (rs18050810 in 
exon 6 and rs1788799 in exon 12) SNP´s allele frequencies in NPC1 gene from centenarians 
through normal controls to sporadic late-onset AD, indicating a role for NPC1 gene in AD and/or 
aging [7]. In addition to this SNP rs18050810 (exon 6) of the original paper, we genotyped other 
SNPs in introns 20, 22 and 24 capturing 85% of NPC1 genetic variability in CEU Hap Map 
population; in our sample,  all the SNPs analyzed were located in a single haplotype block in 
almost complete linkage disequilibrium. Although there are no relevant functional assays of any 
of these NPC1 studied polymorphisms, the most likely mechanism of the association of the 
NPC1 genetic variants with AD is the loss of function of NPC1. The NPC1 is an intracellular 
chaperone involved in the transport of cholesterol from late endosomes/lysosomes to the 
endoplasmic reticulum and the plasma membrane [3]. NPC disease is a progressive neurological 
disorder in which large amounts of cholesterol accumulate in late endosomes/lsysosomes in 
NPC1-deficient cells, caused by mutations in the NPC1 gene [2]. Neurofibrillary tangles have 
been detected in brains of juvenile and adult cases of NPC disease, these tangles being 
immunocytochemically and morphologically indistinguishable from the tangles in AD brains and 
show the same pattern of tau hyperphosphorylation [20]. In addition, tangle-bearing neurons in 
AD contain more unesterified cholesterol than do tangle-free neurons [21] suggesting that a 
sequestration of cholesterol, such as occurs in NPC disease, might influence tangle formation. It 
has been suggested that cholesterol may also modulate Aβ formation, a causative factor of AD 
[1]; so, the intracellular accumulation of cholesterol in the brain of a mouse model of NPC 
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disease enhances amyloidogenesis via enhancement of γ-secretase activity, which correlates with 
an increase in Aβ levels [22]. Recent findings have suggested an interaction of ABCA1 and 
NPC1 proteins in intracellular cholesterol trafficking: in cultured NPC1-deficient fibroblasts 
ABCA1 expression was decreased and the ABCA1-dependent efflux of cholesterol was impaired 
[23].  
Although information about the expression of ABCA1 (−477), NPC1 (exon 6), NPC1 (intron 
20), NPC1 (intron 22), and NPC1 (intron 24) at the brain level in subjects with different 
genotypes is lacking, it is tempting to speculate that a reduction in the expression of ABCA1 and 
NPC1 in carriers of both the ABCA1 (−477) TT genotype and the NPC1 (exon 6) GG genotype, 
NPC1 (intron 20) AA genotype, NPC1 (intron 22) AA genotype, or NPC1 (intron 24) GG 
genotype would lead to higher cholesterol levels in neurons and glial cells, which in turn could 
induce Aβ production and tangle formation and increased AD risk. Our sample size had 90% 
power to detect an OR of 2.0 or higher for an effect of ABCA1 (−477) TT genotype and NPC1 
(intron 20) AA genotype on AD risk. It is noticeable that no association with AD risk was 
obtained from the examination of the main effects of ABCA1 and NPC1 independently, but an 
important result has been derived from the study of their epistatic (gene-gene) interaction [13]. In 
fact, with the current one-SNP-at-a-time approach to genomewide association studies, failure to 
replicate a genetic association in a second sample can be an indication that single SNPs 
contribute to disease susceptibility through interactions with one or more other SNPs [24]. 
Moreover, it has been proposed that patterns of SNPs in biochemical pathways, such as the 
cholesterol trafficking pathway analyzed in the present study, are more likely to replicate than 
individual and non-related SNPs [25]. Additional studies using different sets of patients and 
control subjects are required to verify the validity of our hypotheses (genetic and biologic).  
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    Controls 
ABCA1 (−477) (rs2422493)   
CC 180 (0.29) 197 (0.27) 
CT 285 (0.45) 372 (0.51) 
TT 166 (0.26) 162 (0.22) 
Total 631 731 
Allele frequency C/T 
NPC1 (exon 6) (rs18050810) 
0.51/0.49 0.52/0.48 
AA 259 (0.42) 300 (0.42) 
AG 278 (0.45) 327 (0.45) 
GG 79 (0.13) 97 (0.13) 
Total 616 724 
Allele frequency A/G 




CC 197 (0.32) 222 (0.31) 
CA 300 (0.48) 359 (0.49) 
AA 125 (0.20) 145 (0.20) 
Total 622 726 
Allele frequency C/A 
NPC1 (intron 22) (rs2236707) 
0.56/0.44 0.55/0.45 
GG 230 (0.37) 269 (0.37) 
GA 293 (0.48) 349 (0.48) 
AA 93 (0.15) 109 (0.15) 
Total 616 727 
Allele frequency G/A 
NPC1 (intron 24) (rs2510344) 
0.61/0.39 0.61/0.39 
AA 201 (0.33) 218 (0.30) 
AG 293 (0.47) 364 (0.50) 
GG 124 (0.20) 145 (0.20) 
Total 618 727 




  Figures in parentheses indicate frequencies 
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ABCA1 (−477) TT (−) =CC+CT; NPC1 (exon 6) GG (−) = AA+AG; NPC1 (intron 20) AA (−) = CC+CA; NPC1 (intron 22) AA (−) = GG+GA; NPC1 (intron 






ABCA1 (−477)  
TT genotype 
 
AD cases Controls OR (95% CI)∗ p∗ OR (95% CI) ∗∗ p∗∗ 
 
NPC1  (exon 6) GG genotype        
− − 405 485 1 (Reference)  1 (Reference)  
− + 132 142 1.13 (0.84-1.46) 0.43 1.07 (0.78-1.45) 0.67 
+ − 49 78 0.75 (0.51-1.10) 0.14 0.80 (0.52-1.23) 0.31 
+ + 30 19 1.89 (1.04-3.41) 0.034 1.83 (0.95-3.52) 0.068 
 
NPC1 (intron 20) AA genotype        
− − 383 450 1 (Reference)  1 (Reference)  
− + 114 131 1.02 (0.76-1.36) 0.87 1.01 (0.73-1.39) 0.95 
+ − 76 117 0.76 (0.55-1.05) 0.10 0.85 (0.59-1.22) 0.38 
+ + 49 28 2.05 (1.26-3.33) 0.004 1.85 (1.07-3.18) 0.026 
 
NPC1 (intron 22) AA genotype        
− − 399 479 1 (Reference)  1 (Reference)  
− + 124 139 1.07 (0.81-1.41) 0.62 1.04 (0.76-1.42) 0.78 
+ − 57 88 0.77 (0.54-1.11) 0.16 0.86 (0.58-1.29) 0.58 
+ + 36 21 2.05 (1.18-3.58) 0.01 2.00 (1.07-3.74) 0.028 
 
NPC1 (intron 24) GG genotype        
− − 377 450 1 (Reference)  1 (Reference)  
− + 117 132 1.05 (0.79-1.40) 0.69 1.05 (0.76-1.45) 0.73 
+ − 78 116 0.80 (0.58-1.10) 0.17 0.89 (0.62-1.27) 0.52 
+ + 46 29 1.89 (1.16-3.07) 0.01 1.71 (0.99-2.94) 0.051 
